A GLP-1 telehealth offer can involve several parties: the treating clinician, dispensing pharmacy and platform that bills for services. A membership is one possible payment model, not a requirement of telehealth. Knowing which of the three you're paying for, and checking each against FDA's own warning signs, tells you more than the headline price [2].
What GLP-1 telehealth is
It is an assessment by a clinician authorized to treat the patient, with a prescription only if appropriate. Dispensing may involve delivery or pharmacy pickup. The visit may be a video call, a phone call or a written medical questionnaire reviewed by a clinician. The prescription can be for a brand-name drug or a compounded one. The pharmacy can be a regular retail or mail-order pharmacy, or a compounding pharmacy.
Service and payment arrangements vary. Some programs charge one monthly price that includes the drug. Others charge a membership on top of the drug, or bill the visit separately. That's why the medication quote alone may not establish the full cost of care.
The route decides what's in the box and who checks it
| Route | What you get | FDA-approved? | Who fills it | Price context | Read more |
|---|---|---|---|---|---|
| Brand through a telehealth program | Wegovy, Zepbound or Foundayo for weight; Ozempic or Mounjaro for type 2 diabetes | Yes | Licensed retail or mail-order pharmacy | Check exact-plan coverage, applicable manufacturer offers and separate service fees | Wegovy · Zepbound |
| Brand through the maker's self-pay program, after a prescription | Zepbound vials or KwikPen (LillyDirect); Wegovy pens or pills (NovoCare) | Yes | The maker's partner pharmacy | Zepbound from $299 a month at the starting dose; Wegovy pill from $149; Wegovy pen $349 after an intro offer | Zepbound cost · Wegovy cost |
| Compounded semaglutide or tirzepatide | A pharmacy-prepared drug with a specific formulation, concentration and dispensing label | No | A compounding pharmacy (503A) or an outsourcing facility (503B) | Request the amount due now, renewal interval and separate clinical/laboratory costs | Compounded semaglutide · compounded tirzepatide |
Maker prices from LillyDirect and NovoCare. Eligibility and formulation-specific offer conditions apply; these categories are not prescribing or dispensing guarantees.
The maker prices have conditions. On LillyDirect, Zepbound costs $299 a month at 2.5 mg and $399 at 5 mg; the higher doses are $449 "when you refill within 45 days," and otherwise $499 or $699 [5]. Lilly notes that 2.5 mg is for initiation rather than approved maintenance. Its pricing month is 28 days; needles, taxes and fees may be additional, and the offer can change. On NovoCare, the Wegovy pill starts at $149 a month, and new patients pay $199 for each of their first two monthly fills of the two lowest pen doses through December 31, 2026, "then $349 per month" [6]. The tablet headline covers 30 initiation-strength tablets, not every maintenance strength; Wegovy’s higher-strength injection has a separate price. These are eligible package offers rather than a guaranteed annual quote.
A legitimate program asks the questions the drug labels require
The labels of the GLP-1 brands list who shouldn't take them and which situations need care. The clinical evaluation must assess the relevant contraindications and precautions before prescribing. FDA warns against providing medicine without the required screening and prescription [2].
- Allergy and thyroid history. Serious hypersensitivity to the relevant drug or its ingredients is also a contraindication. A personal or family history of medullary thyroid carcinoma, or MEN 2, rules out all five brands [7] [8] [9] [10] [11]. See Wegovy and thyroid cancer.
- Pregnancy plans. Wegovy's and Ozempic's labels say to stop at least 2 months before a planned pregnancy; Zepbound's and Foundayo's say to stop when pregnancy is recognized [7] [8] [9] [11].
- Birth-control pills. Tirzepatide and Foundayo can make oral contraceptives less reliable for a period after starting and after each dose increase [9] [11].
- Stomach and pancreas. Severe gastroparesis is a caution on the labels, and pancreatitis is a listed warning [8] [10].
- Other diabetes medicines. Insulin or a sulfonylurea raises the risk of low blood sugar with any of these drugs [8] [10].
Expect questions about your weight history, other medicines and existing conditions, and sometimes a request for recent lab results. Payment before assessment does not by itself establish inadequate care, but payment or an intake form is not a substitute for clinical review. Ask what is refundable if the clinician declines treatment.
Who fills the prescription matters as much as who writes it
Brand GLP-1s come from licensed retail or mail-order pharmacies. Compounded versions come from compounding pharmacies, and FDA doesn't approve what they make. There are two kinds. A 503A pharmacy is a state-licensed pharmacy that compounds for individual patients' prescriptions; a registered 503B outsourcing facility operates under a different federal framework; registration does not approve its products [3].
If a program doesn't name its pharmacy, ask. Once you know it, you can look the pharmacy up with your state board of pharmacy. FDA's red flags include a pharmacy name on the label "that you think might be fraudulent" and incorrect pharmacy addresses [2].
FDA publishes seven warning signs for telehealth GLP-1 offers
| Warning sign summarized from FDA | What to check instead |
|---|---|
| Claims of equivalence to an approved product | Identify the exact preparation; a shared ingredient is not approval or proven product equivalence |
| An implausibly low advertised price | Check the full commitment, contents, pharmacy and recurring terms |
| Unexpected appearance, damaged packaging or missing instructions | Contact the pharmacist and treating team before using a questionable supply |
| No screening and prescription before medicine is provided | Confirm who performs the clinical assessment and whether they are authorized to treat you |
| No clinician available after delivery | Ask how to obtain follow-up and urgent guidance |
| Label errors or an incorrect pharmacy address | Verify the actual dispensing label against the pharmacy’s record |
| A potentially fraudulent pharmacy name | Check the relevant state-board record; a platform logo is not a pharmacy license |
FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss."
Both shortages are over, so compounding now runs under narrower rules
FDA reaffirmed its earlier tirzepatide shortage resolution in a decision dated December 19, 2024, and the semaglutide shortage resolved on February 21, 2025 [3]. After litigation-related extensions, FDA said the 503A tirzepatide period ended following the March 5, 2025 court decision, and the semaglutide period ended following the April 24 decision. For outsourcing facilities they ended March 19, 2025 and May 22, 2025. FDA's April 2026 update says neither drug appears on its shortage list.
The four-prescription policy concerns enforcement discretion over essentially-copy compounding, not a statutory permission slip or exemption from other conditions. A documented significant difference for an identified patient can affect that analysis. The May 2026 proposal addresses the 503B bulk-ingredient clinical-need list, not every outsourcing-facility pathway or every 503A prescription [3] [4]. The details are in tirzepatide availability and semaglutide regulatory status.
Costs split into the drug, the membership and sometimes labs
Compare the whole monthly total, not the advertised number. Ask whether the price covers the drug at every dose, whether it rises as your dose goes up, and whether visits or lab work cost extra. The cost guides for compounded semaglutide and compounded tirzepatide break this down by program, and the monthly cost calculator turns any plan's billing into one monthly figure.
If you're on Medicare, the separate GLP-1 Bridge charges $50 for a qualifying 28- or 30-day supply for Wegovy, Zepbound KwikPen or Foundayo for weight management if you qualify. Zepbound coverage is KwikPen only, not its single-dose pens or vials. Prior authorization and clinical criteria apply; Bridge payments are outside Part D and cannot use its Prescription Payment Plan [12] [1]. See Medicare coverage for Ozempic and the Bridge.
Ask who prescribes, who fills it, what's included and how to cancel
- Who reviews my intake, and are they licensed in my state?
- Is this an FDA-approved brand or a compounded drug?
- Which pharmacy fills it, and is it a 503A pharmacy or a 503B outsourcing facility?
- What does the monthly price include, and does it change at higher doses?
- How do I reach a clinician after the medicine arrives?
- How do I pause or cancel, and is there a minimum commitment?
Programs that answer these on their own site make the check easy. Our scored lists of compounded semaglutide programs and compounded tirzepatide programs show how each one fares, sorted by score as explained in how we score. Step-by-step access is covered in how to get compounded semaglutide and where to get compounded tirzepatide. Pills are covered in oral semaglutide and on the orforglipron (Foundayo) guide.